We Claim:

1. An oral dosage form of modafinil comprising modafinil and one or more surface active agents.

2. The oral dosage form of modafinil of claim 1, wherein:
the modafinil comprises fine and coarse modafinil particles;
at least 10% of the modafinil particles comprise coarse modafinil particles and have diameters greater than 220 μm; and
up to 90% of the modafinil particles.comprise fine modafinil particles and have diameters less than 220 μm.

3. The oral dosage form of modafinil of claim 1, wherein:
the modafinil comprises fine and coarse modafinil particles;
at least 15% of the modafinil particles comprise coarse modafinil particles and have diameters greater than 220 μm; and
up to 85% of modafinil particles comprise fine modafinil particles and have diameters less than 220 μm.

4. The oral dosage form of modafinil of claim 1, wherein:
the modafinil comprises fine and coarse modafinil particles;
at least 25% of the modafinil particles comprise coarse modafinil particles and have diameters greater than 220 μm; and
up to 75% of the modafinil particles comprise fine modafinil particles and have diameter less than 220 μm.

5. The oral dosage form of modafinil of claim 2, wherein the total specific surface area of the fine modafinil particles is at least 0.2 m^2/g.

6. The oral dosage form of modafinil of claim 1, wherein the modafinil and the one or more surface active agents are co-grinded and/or co-sifted.

7. The oral dosage form of modafinil of claim 1, wherein the surface active agent comprises one or more of an anionic, cationic or non-ionic surface active agent.

8. The oral dosage form of modafinil of claim 7, wherein the anionic surface active agent comprises one or more of sodium lauryl sulphate, sodium laurate, dialkyl sodium sulfosuccinates, sodium stearate, potassium stearate, and sodium oleate.

9. The oral dosage form of modafinil of claim 8, wherein the anionic surface active agent comprises sodium lauryl sulphate.

10. The oral dosage form of modafinil of claim 7, wherein the cationic surface active agent comprise one or both of benzalkonium chloride and bis-2-hydroxyethyl oleyl amine.

11. The oral dosage form of modafinil of claim 7, wherein the non-ionic surface active agent comprises one or more of polyoxyethylene sorbitan fatty acid esters, fatty alcohols, glyceryl esters, fatty acid esters of fatty alcohols, and alcohols.

12. The oral dosage form of modafinil of claim 11, wherein the fatty alcohol comprises one or more of lauryl, cetyl and stearyl alcohol.

13. The oral dosage form of modafinil of claim 11, wherein the glyceryl esters comprises one or more naturally occurring monoglycerides, diglycerides and triglycerides.

14. The oral dosage form of modafinil of claim 11, wherein the alcohol is selected from one or more of propylene glycol, polyethylene glycol, sorbitan, sucrose and cholesterol.

15. The oral dosage form of modafinil of claim 11, wherein the polyethylene sorbitan fatty acid ester comprises polysorbate.

16. The oral dosage form of modafinil of claim 1, wherein the amount of surface active agent comprises from about 0.2% to 10% by weight, of the total weight of the dosage form.

17. The oral dosage form of modafinil of claim 1, further comprising one or more pharmaceutically inert carriers, wherein the one or more pharmaceutically inert carriers comprise one or more of cellulose derivatives, silicate derivatives, and clays.

18. The oral dosage form of modafinil of claim 17, wherein the cellulose derivative comprises one or both of microcrystalline cellulose and carboxymethylcellulose.

19. The oral dosage form of modafinil of claim 17, wherein the silicate derivative comprises one or more of magnesium silicate, colloidal silicon dioxide, magnesium trisilicate, and magnesium aluminum silicate.

20. The oral dosage form of modafinil of claim 17, wherein the clay comprises one or more of veegum and bentonite.

21. The oral dosage form of modafinil of claim 1, wherein the amount of pharmaceutically inert carrier comprises from about 2% to about 25% by weight, of total weight of the dosage form.

22. The oral dosage form of modafinil of claim 1, wherein the dosage form comprises a tablet, a capsule, or a pill.

23. The oral dosage form of modafinil of claim 22, wherein the dosage form comprises a tablet.

24. The oral dosage form of modafinil of claim 1, wherein the dosage form further comprises one or more pharmaceutically inert excipients.

25. The oral dosage form of modafinil of claim 24, wherein the pharmaceutically inert excipient comprises one or more of diluents, binders, disintegrants, lubricants/glidants and colors.

26. A process for preparing an oral dosage form of modafinil, the process comprising the steps of:

a. mixing modafinil and one or both of one or more surface active agents and one or more pharmaceutically inert carriers;
b. grinding and/or sifting the mix of step a;
c. combining with pharmaceutically inert excipients; and
d. compressing or filling into a suitable dosage form.

27. The process according to claim 26, wherein:
the modafinil comprises fine and coarse modafinil particles;
at least 10% of the modafinil particles comprise coarse modafinil particles and have bn diameters greater than 220 μm; and
up to 90% of the modafinil particles comprise fine modafinil particles and have diameters less than 220 μm.

28. The process according to claim 26, wherein:

the modafinil comprises fine and coarse modafinil particles;

at least 15% of the modafinil particles comprise coarse modafinil particles and have diameters greater than 220 μm; and

up to 85% of the modafinil particles comprise fine modafinil particles and have diameters less than 220 μm.

29. The process according to claim 27, wherein:

the modafinil comprises fine and coarse modafinil particles;

at least 25% of the modafinil particles comprise coarse modafinil particles and have diameters greater than 220 μm; and

up to 75% of the modafinil particles comprise fine modafinil particles and have diameters less than 220 μm.

30. The process according to claim 26, wherein the total specific surface area of the fine modafinil particles is at least 0.2 m^2/g.

31. The process according to claim 26, wherein the dosage form comprises one or more of a tablet, a capsule, and a pill.

32. The process according to claim 31, wherein the dosage form comprises a tablet.

33. The process according to claim 32, wherein the tablet is prepared by one or more of a process of wet granulation, dry granulation, or direct compression method.

34. The process according to claim 33, wherein the tablet is prepared by a wet granulation method.

35. The process according to claim 33, wherein the tablet is prepared by a dry granulation method.

36. The process according to claim 33, wherein the tablet is prepared by a direct compression method.

37. The process according to claim 31, wherein the dosage form comprises a capsule.

38. The process according to claim 32, wherein the dosage form is coated with one or more functional and/or non-functional layers.

39. A method of treating one or both of narcolepsy and idiopathic hypersomnia by administering an oral dosage form of modafinil, the dosage form comprising coarse and fine modafinil particles and one or more surface active agents, wherein the fine modafinil particles have diameters less than 220 μm.

40. The method according to claim 39, wherein at least 10% of the modafinil particles have diameters greater than 220 μm.

41. The method according to claim 40, wherein at least 15% of the modafinil particles have diameters greater than 220 μm.

42. The method according to claim 41, wherein at least 25% of the modafinil particles have diameters greater than 220 μm.

43. The method according to claim 39, wherein the total specific surface area of the fine modafinil particles is at least 0.2 m^2/g.

44. A mixture comprising modafinil particles and one or both of one or more surface active agents and one or more pharmaceutically inert carriers, wherein the mixture is one or both of co-grinded and co-sifted.

45. The mixture according to claim 44, wherein:
at least 10% of the modafinil particles are coarse and have diameters greater than 220 μm; and
up to 90% of the modafinil particles are fine and have diameters less than 220 μm.

46. The mixture according to claim 45, wherein:
at least 15% of the modafinil particles are coarse and have diameter greater than 220 μm; and
up to 85% of the modafinil particles are fine having diameter less than 220 μm.

47. The mixture according to claim 46, wherein:

at least 25% of the modafinil particles are coarse and have diameters greater than 220 μm; and

up to 75% of the modafinil particles are fine and have diameters less than 220 μm.

48. The mixture according to claim 44, wherein the total specific surface area of the fine modafinil particles is at least 0.2 m^2/g, the fine modafinil particles having diameters less than 220 μm.

49. An oral dosage form of modafinil comprising modafinil and one or more surface active agents, wherein the one or more surface active agents comprises one or more of an anionic, cationic or non-ionic surface active agent.

50. The oral dosage form of modafinil of claim 49, wherein:
the modafinil comprises fine and coarse modafinil particles;
at least 10% of the modafinil particles comprise coarse modafinil particles and have diameters greater than 220 μm; and
up to 90% of the modafinil particles comprise coarse modafinil particles and have diameters less than 220 μm.

51. The oral dosage form of modafinil of claim 49, wherein:
the anionic surface active agent comprises one or more of sodium lauryl sulphate, sodium laurate, dialkyl sodium sulfosuccinates, sodium stearate, potassium stearate, and sodium oleate;
the cationic surface active agent comprises one or both of benzalkonium chloride and bis-2-hydroxyethyl oleyl amine; and
the non-ionic surface active agent comprises one or more of polyoxyethylene sorbitan fatty acid esters, fatty alcohols, glyceryl esters, fatty acid esters of fatty alcohols, and alcohols.

52. The oral dosage form of modafinil of claim 50, further comprising one or more pharmaceutically inert carriers, wherein the one or more pharmaceutically inert carriers comprise one or more of cellulose derivatives, silicate derivatives, and clays.

53. The oral dosage form of modafinil of claim 49, further comprising one or more additional active pharmaceutical ingredients.

54. An oral dosage form of modafinil comprising modafinil and one or both of one or more surface active agents and one or more pharmaceutically inert carriers;

wherein the one or more surface active agents comprise one or more of an anionic, cationic or non-ionic surface active agent; and

wherein the one or more pharmaceutically inert carrier comprise clay.